Top Markets
#1 DogBull DogBull +108.92%
#2 MarsCoin MarsCoin +75.44%
#3 Siacoin Siacoin +55.80%
#4 ADO Protocol ADO Protocol +52.90%
#5 The Bitcoin Bull The Bitcoin Bull +26.92%
#6 Ontology Gas Ontology Gas +22.45%
#7 Useless Coin Useless Coin +17.91%
#8 Apertum Apertum +14.84%
#9 Arowana Arowana +12.72%
#10 UnifAI Network UnifAI Network +11.97%
Coin of the day
DogBull DogBull
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Hansa Biopharma AB Hansa Biopharma AB

Hansa Biopharma AB

HNSBF
Classifica tra le azioni #15162
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development... Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Prezzo delle azioni
$3.70
Ultima sincronizzazione: 2026-08-28
Capitalizzazione di mercato
$369.01M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
35.04%
Paese
SE
Scambia Hansa Biopharma AB (HNSBF)

Categoria

Healthcare
Storico dividendi per Hansa Biopharma AB (HNSBF)
Hansa Biopharma AB (simbolo azionario: HNSBF) ha effettuato un totale di 0 pagamenti di dividendi.
La somma totale dei dividendi (rettificata per split azionari) è: 0.00
Rendimento da dividendo (TTM): 0
Pagamenti dei dividendi per Hansa Biopharma AB (HNSBF) dal 2026 al 2026
Pagamenti annuali dei dividendi
Anno Dividendo (rettificato per split azionari) Cambia
Non abbastanza dati per le date fornite.
Elenco di tutti i pagamenti di dividendi
Anno Dividendo Cambia
Non abbastanza dati per le date fornite.
Dividendi di aziende simili o concorrenti
Azienda Numero di pagamenti di dividendi Il paese
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
23.00%
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
0.00%
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
0.00%
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
0.00%
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
0.00%
US